Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate-to-severe psoriasis: 24-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H)
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Nail psoriasis is common in patients with psoriatic arthritis and psoriasis, affecting as many as 80% to 90% of those with psoriasis at some time in their life.
- This post-hoc subgroup analysis of the SPIRIT-H2H study (NCT03151551) compared the efficacy of the IL-17A antagonist ixekizumab and the TNF-alfa blocker adalimumab for resolving nail psoriasis to Week 24 in patients with active psoriatic arthritis and moderate-to-severe psoriasis.
- In this post-hoc analysis, ixekizumab (80.0%) showed significantly higher rates of complete resolution of nail involvement than adalimumab (52.5%) at Week 24, confirming the established efficacy of ixekizumab in nail psoriasis.
- This confirms the established efficacy of ixekizumab in nail psoriasis.
Presenting Author
Saxon D. Smith, MBChB, MHL, PhD
Northern Clinical School, Sydney Medical School, The University of Sydney
Sydney, Australia
Dr Saxon D Smith is a Fellow of the Australasian College of Dermatologists. He graduated medicine from the University of Otago, Dunedin, New Zealand, and has a Master Degree in Health Law from the University of Sydney. He completed his Doctor of Philosophy (Medicine) at the University of Sydney.
Dr Smith is the principal dermatologist at The Dermatology and Skin Cancer Centre in Gosford and St Leonards, NSW, Australia. He has been a clinical supervisor for dermatology trainees, higher degree by research students, and University of Sydney Doctorate of Medicine (MD) research supervisor/tutor. He has performed research in a broad range of areas in medical and surgical dermatology including adult and paediatric atopic dermatitis, adult and paediatric psoriasis, hidradentitis suppurativa, as well as the surgical and non-surgical management of non-melanoma skin cancer and melanoma. He is also currently involved in multiple pharmaceutical trials from phase II to phase IV.
Dr Smith has been a key note speaker and invited speaker to national and international conferences. He has over 75 peer reviewed journal publications and over 100 published abstracts.
Author disclosures
Saxon D. Smith: Advisory Panel: Abbvie, Biogen, Eli Lilly and Company, Janssen-Cilag, Johnson and Johnson Consumer Products Company, Novartis, Pfizer, Sanofi Genzyme; Research Support: Abbvie, BMS, Eli Lilly and Company, Novartis, Sanofi Genzyme, UCB, Regeneron; Speaker’s Bureau: Abbvie, Eli Lilly and Company, Leo, Novartis; Honoraria: Energizer Holdings, Inc.
